“The existing scenario has uncovered some structural weaknesses while in the EU’s medicines supply chain along with a high dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides explained. She advisable that offer chain concerns be tackled in an EU pharmaceutical tactic ex